Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Titre
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Sujet
Description
Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic.
Date
2020-06-11
Type
Citer ce document
Stringhini, Silvia, Ania Wisniak, Giovanni Piumatti, Andrew S. Azman, Stephen A. Lauer, Hélène Baysson, David De Ridder, Dusan Petrovic, Stephanie Schrempft, Kailing Marcus, Sabine Yerly, Isabelle Arm Vernez, Olivia Keiser, Samia Hurst, Klara M. Posfay-Barbe, Didier Trono, Didier Pittet, Laurent Gétaz, François Chappuis, Isabella Eckerle, Nicolas Vuilleumier, Benjamin Meyer, Antoine Flahault, Laurent Kaiser, and Idris Guessous. 2020. "Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study." The Lancet.
Accessibilité
Free online on Lancet site.
Was this resource helpful?